IPP Bureau
Novo Nordisk India sets patient-centred price of Rs. 202/day for starting dose of Ozempic and Wegovy
By IPP Bureau - March 31, 2026
Price of the starting dose of Ozempic and Wegovy reduced by 36% and 48% respectively
Sun Pharma to spotlight 14 dermatology studies at 2026 AAD annual meeting
By IPP Bureau - March 30, 2026
The presentations underscore the company’s deep expertise in dermatology and immunology
Eli Lilly trial shows combo therapy dramatically improves psoriatic arthritis, obesity outcomes
By IPP Bureau - March 30, 2026
The findings were presented as a late-breaking study at the 2026 American Academy of Dermatology
Rocket Pharma gets FDA nod for first pediatric gene therapy targeting severe LAD-I
By IPP Bureau - March 29, 2026
The approval covers pediatric patients without a matched sibling donor for stem cell transplant
Philanthropist Ludacris teams up with One A Day to make health simple
By IPP Bureau - March 29, 2026
The campaign highlights a straightforward, achievable approach to health, proving that supporting your wellness doesn’t have to be complicated
Philips launches game-changing interventional platform for cardiology
By IPP Bureau - March 29, 2026
IntraSight Plus enables confident decision-making and better patient care,” Philips said, emphasizing efficiency, simplicity, and precision
Alembic receives USFDA final approval for Paroxetine Extended-Release Tablets
By IPP Bureau - March 28, 2026
Paroxetine extended-release tablets are indicated for the treatment of major depressive disorder
Shreehas Tambe appointed CEO & Managing Director of Biocon
By IPP Bureau - March 28, 2026
Kedar Upadhye has also been appointed as Chief Financial Officer of Biocon Limited
Novartis acquires Excellergy to bolster allergy portfolio
By IPP Bureau - March 28, 2026
The move leverages Novartis’ deep expertise in IgE biology and long-standing presence in allergic disease treatments
AbbVie stakes claim to redefine skin disease treatment at Global Dermatology Summit
By IPP Bureau - March 28, 2026
Beyond clinical trials, real-world evidence is adding weight to AbbVie’s claims
Eli Lilly drug shows 4-year relief for eczema patients, study finds
By IPP Bureau - March 28, 2026
The therapy works by targeting interleukin-13, a key driver of inflammation behind eczema symptoms such as itching, skin damage, and infection
AstraZeneca’s breakthrough COPD drug Tozorakimab slashes flare-ups in landmark Phase III trials
By IPP Bureau - March 28, 2026
High-level results from the Phase III OBERON and TITANIA trials revealed that the first-in-class monoclonal antibody reduced the annual rate of moderate-to-severe COPD exacerbations compared with placebo
Otsuka Pharma to acquire Transcend Therapeutics in $1.225 billion deal
By IPP Bureau - March 28, 2026
Otsuka will pay $700 million to Transcend shareholders at closing, with an additional $525 million in contingent payments tied to future sales milestones
Lonza launches Singapore Media Development Lab to cut biomanufacturing risk
By IPP Bureau - March 27, 2026
The move comes as drug developers face mounting pressure from faster timelines and increasingly complex manufacturing processes
MGM Healthcare builds world’s largest intestinal transplant program in 3 years
By IPP Bureau - March 27, 2026
Since launching, the hospital has performed over 40 intestinal transplants, including 21 in 2025 alone
